May 15, 2019 / 10:00PM GMT
Alan H. Auerbach - Puma Biotechnology, Inc. - Founder, Chairman, President, CEO & Secretary
And welcome to the Puma Biotechnology presentation. We have only been given 15 minutes for the presentation, so I'm going to skip through some of the slides, but my understanding is they will be available online for investors to view.
So first a reminder, I'll be making forward-looking statements. So on this slide you can see our product pipeline for neratinib. As you can see, the drug is on the market in the extended adjuvant. It has been approved in the United States and in Europe. And that was based on the results of our Phase III ExteNET study. We also have an ongoing Phase II study as well known as the CONTROL study, in which we're looking at decreasing the side effects of the drug. We also, as you can see on slide, have 3 ongoing metastatic trials, the NALA trial, which is our Phase III in third line HER2-positive breast. And then 2 Phase IIs as well. We also have a specific trial in patients with brain mets, which is the TBCRC 022 trial. And then we are also looking at specific area of HER2
Puma Biotechnology Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers